New sedative shows promise for Long-Term ICU sedation
NCT ID NCT05913336
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested a sedative called remimazolam tosilate in 24 ICU patients who needed to be on a breathing machine for at least three days. The goal was to see if the drug could keep patients at the right sedation level safely. Because this is a small, non-randomized study, the results are preliminary and more research is needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
remimazolam tosilate
What this could lead to
If successful, this could provide a safer or more controllable sedation option for ICU patients who need to be on a breathing machine for days.
What could go wrong
This is a very early, small study (24 people) with no comparison group, so results may not apply broadly. The drug may not work as well as current sedatives or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEDATION IN THE ICU are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, 550001, China